The Company’s main focus is on vaccine technologies. BioDiem’s leading product is the Live Attenuated Influenza Virus (LAIV) technology, a novel intranasal vaccine being developed to prevent infection from seasonal and pandemic influenza. It has been launched in India as Nasovac™ for protection against H1N1 influenza. The LAIV technology is also being investigated for use as a viral vector platform.

The BDM-E (ophthalmic indications) and BDM-I (antimicrobial indications) projects are in the process of being more thoroughly researched in order to create data packages and strengthened intellectual property positions, The results of the studies are being collated for a due diligence package with the aim to outlicense or sell the technologies.